Efficacy and tolerance of osilodrostat in patients with Cushing’s syndrome due to adrenocortical carcinomas

in European Journal of Endocrinology
View More View Less
  • 1 Department of Endocrinology, Diabetes and Nutrition, Hôpital Haut Lévêque, CHU and University of Bordeaux, Pessac, France
  • | 2 Fédération d’Endocrinologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France
  • | 3 Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital and University of Lille, Lille, France
  • | 4 Department of Endocrinology, Diabetes and Nutrition, Médipole Lyon Villeurbanne, Villeurbanne, France
  • | 5 University Grenoble Alpes, Service d’Endocrinologie CHU Grenoble Alpes, Unité Mixte de Recherche INSERM-CEA-UGA UMR1036, Grenoble Alpes, France
  • | 6 Department of Reproductive Endocrinology, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre and University Paris-Saclay, Paris, France

Correspondence should be addressed to A Tabarin Email antoine.tabarin@chu-bordeaux.fr
Restricted access

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 1745 1745 160
Full Text Views 163 163 13
PDF Downloads 227 227 21
  • 1

    Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, Haak HR, Mihai R, Assie G, Terzolo M. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the study of adrenal tumors. European Journal of Endocrinology 2018 179 G1G46. (https://doi.org/10.1530/EJE-18-0608)

    • Search Google Scholar
    • Export Citation
  • 2

    Puglisi S, Perotti P, Pia A, Reimondo G, Terzolo M. Adrenocortical carcinoma with hypercortisolism. Endocrinology and Metabolism Clinics of North America 2018 47 395407. (https://doi.org/10.1016/j.ecl.2018.02.003)

    • Search Google Scholar
    • Export Citation
  • 3

    Corcuff JB, Young J, Masquefa-Giraud P, Chanson P, Baudin E, Tabarin A. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. European Journal of Endocrinology 2015 172 473481. (https://doi.org/10.1530/EJE-14-0913)

    • Search Google Scholar
    • Export Citation
  • 4

    Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R & Lee EJ et al.Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet: Diabetes and Endocrinology 2020 8 748761. (https://doi.org/10.1016/S2213-8587(2030240-0)

    • Search Google Scholar
    • Export Citation
  • 5

    Haissaguerre M, Puerto M, Nunes ML, Tabarin A. Efficacy and tolerance of osilodrostat in patients with severe Cushing’s syndrome due to non-pituitary cancers. European Journal of Endocrinology 2020 183 L7L9. (https://doi.org/10.1530/EJE-20-0557)

    • Search Google Scholar
    • Export Citation
  • 6

    Baudry C, Coste J, Bou Khalil R, Silvera S, Guignat L, Guibourdenche J, Abbas H, Legmann P, Bertagna X, Bertherat J. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. European Journal of Endocrinology 2012 167 473481. (https://doi.org/10.1530/EJE-12-0358)

    • Search Google Scholar
    • Export Citation
  • 7

    Bessiene L, Bonnet F, Tenenbaum F, Jozwiak M, Corchia A, Bertherat J, Groussin L. Rapid control of severe ectopic Cushing’s syndrome by oral osilodrostat monotherapy. European Journal of Endocrinology 2021 184 L13L15. (https://doi.org/10.1530/EJE-21-0147)

    • Search Google Scholar
    • Export Citation